Exscientia’s tree sculpture logo is based on a sketch found in Darwin’s notebook where he first proposed a theory of evolution and natural selection. Developing AI to be creative follows similar principles to evolution to generate new ideas and using models to select the best.
Explore
Better drugs faster
Welcome to the world’s leading pharmatech, using AI to precision engineer future drugs for patients and revolutionise drug discovery.
Our pipeline
Our carefully engineered systems combine advanced AI design with exacting experimental validation to rapidly progress a pipeline of drug discovery assets.
Exscientia are spearheading the drug discovery revolution with the first AI-Designed molecules to reach clinic trials.
Clinical Impact
Ground-breaking clinical impact. Our Patient-first AI platform has already demonstrated improved treatment outcomes in a prospective interventional study
Our carefully engineered systems combine advanced AI design with exacting experimental validation to rapidly progress a pipeline of drug discovery assets.
Exscientia are spearheading the drug discovery revolution with the first AI-Designed molecules to reach clinic trials.
Clinical Impact
Ground-breaking clinical impact. Our Patient-first AI platform has already demonstrated improved treatment outcomes in a prospective interventional study
Our carefully engineered systems combine advanced AI design with exacting experimental validation to rapidly progress a pipeline of drug discovery assets.
We only need to test 1/10th of the compounds traditionally required.
Quality
We design against key criteria from the outset baking in all the properties needed for a successful drug.
Unprecedented speed
From project start to candidate
molecule in less than 1 year.
Applying AI to drug design is recognised as one of the ultimate scientific challenges
Smarter design decisions with AI
Navigating Chemical Space
Whilst there are trillions of potential molecules, few will ever be made and only a handful fulfill the complex criteria required to warrant testing in the clinic.
Learning efficiently with AI
Drug discovery is best thought of as a learning problem. Faster learning identifies compounds that fit a project’s clinical brief more rapidly and efficiently.
Exscientia AI
Exscientia AI systems are better at learning than traditional human-led design allowing molecules to reach the clinic faster.
Higher performance with AI
Efficient
We only need to test 1/10th of the compounds traditionally required.
Quality
We design against key criteria from the outset baking in all the properties needed for a successful drug.
Unprecedented speed
From project start to candidate
molecule in less than 1 year.
Applying AI to drug design is recognised as one of the ultimate scientific challenges
Smarter design decisions with AI
Navigating Chemical Space
Whilst there are trillions of potential molecules, few will ever be made and only a handful fulfill the complex criteria required to warrant testing in the clinic.
Learning efficiently with AI
Drug discovery is best thought of as a learning problem. Faster learning identifies compounds that fit a project’s clinical brief more rapidly and efficiently.
Exscientia AI
Exscientia AI systems are better at learning than traditional human-led design allowing molecules to reach the clinic faster.
Higher performance with AI
Efficient
We only need to test 1/10th of the compounds traditionally required.
Quality
We design against key criteria from the outset baking in all the properties needed for a successful drug.
Unprecedented speed
From project start to candidate
molecule in less than 1 year.
The pharmaceutical industry has only recently acknowledged the potential of AI. Projects still routinely require 2000-3000 molecules to be made over many years before a single compound suitable for clinical testing is trialed.
Exscientia AI directly challenges this metric by requiring each newly designed molecule to add the maximum information and shorten the path to a clinical molecule.
Faster by design
At Exscientia we put AI algorithms at the heart of design and data interpretation.
Better by design
Our AI systems optimise properties in parallel rather than sequentially.
Better by design
Using AI to design and optimise molecular properties in parallel, rather than sequentially, increases the likelihood of discovering a candidate with exquisitely balanced pharmacology that will deliver therapeutic benefit in the clinic.
Faster by design
By putting AI at the heart of design as well as data interpretation, we put faith in its ability to rapidly identify optimal drug discovery paths. Through more efficient learning the systems determine the next step faster than incumbent methods.
Precision design
The results speak for themselves, with high quality clinical molecules being invented within a fraction of the compounds typically required, dramatically shortening the path to the clinic.
Revolutionising drug discovery
The pharmaceutical industry has only recently acknowledged the potential of AI. Projects still routinely require 2000-3000 molecules to be made over many years before a single compound suitable for clinical testing is trialed.
Exscientia AI directly challenges this metric by requiring each newly designed molecule to add the maximum information and shorten the path to a clinical molecule.
Faster by design
At Exscientia we put AI algorithms at the heart of design and data interpretation.
Better by design
Our AI systems optimise properties in parallel rather than sequentially.
Better by design
Using AI to design and optimise molecular properties in parallel, rather than sequentially, increases the likelihood of discovering a candidate with exquisitely balanced pharmacology that will deliver therapeutic benefit in the clinic.
Faster by design
By putting AI at the heart of design as well as data interpretation, we put faith in its ability to rapidly identify optimal drug discovery paths. Through more efficient learning the systems determine the next step faster than incumbent methods.
Precision design
The results speak for themselves, with high quality clinical molecules being invented within a fraction of the compounds typically required, dramatically shortening the path to the clinic.
Revolutionising drug discovery
The pharmaceutical industry has only recently acknowledged the potential of AI. Projects still routinely require 2000-3000 molecules to be made over many years before a single compound suitable for clinical testing is trialed.
Exscientia AI directly challenges this metric by requiring each newly designed molecule to add the maximum information and shorten the path to a clinical molecule.
Faster by design
At Exscientia we put AI algorithms at the heart of design and data interpretation.
Better by design
Our AI systems optimise properties in parallel rather than sequentially.
Better by design
Using AI to design and optimise molecular properties in parallel, rather than sequentially, increases the likelihood of discovering a candidate with exquisitely balanced pharmacology that will deliver therapeutic benefit in the clinic.
Faster by design
By putting AI at the heart of design as well as data interpretation, we put faith in its ability to rapidly identify optimal drug discovery paths. Through more efficient learning the systems determine the next step faster than incumbent methods.
Precision design
The results speak for themselves, with high quality clinical molecules being invented within a fraction of the compounds typically required, dramatically shortening the path to the clinic.
Faster learning shortens discovery times and improves outcomes. AI is simply better at learning from complex data sets than humans and better at determining what to do next. We demonstrated this with our ‘Human vs Machine’ data, published in Nature. The results were clear.
We are a creative, passionate and collaborative organisation dedicated to setting bold new standards in drug discovery and design. If you have the ingenuity, energy and ambition to help us change the world, we would love to hear from you.
